2nd International Adalat® Symposium: New Therapy of Ischemic Heart Disease
Editat de W. Lochner, W. Braasch, G. Kronebergen Limba Engleză Paperback – 30 noi 1975
Preț: 723.93 lei
Preț vechi: 762.04 lei
-5% Nou
Puncte Express: 1086
Preț estimativ în valută:
138.56€ • 144.11$ • 116.11£
138.56€ • 144.11$ • 116.11£
Carte tipărită la comandă
Livrare economică 13-27 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783540074717
ISBN-10: 3540074716
Pagini: 392
Ilustrații: XVIII, 372 p.
Dimensiuni: 170 x 244 x 21 mm
Greutate: 0.62 kg
Editura: Springer Berlin, Heidelberg
Colecția Springer
Locul publicării:Berlin, Heidelberg, Germany
ISBN-10: 3540074716
Pagini: 392
Ilustrații: XVIII, 372 p.
Dimensiuni: 170 x 244 x 21 mm
Greutate: 0.62 kg
Editura: Springer Berlin, Heidelberg
Colecția Springer
Locul publicării:Berlin, Heidelberg, Germany
Public țintă
ResearchDescriere
The First Adalat Symposium held in Tokyo in 1973, presented important experimental and clinical results which had been collected in Europe and Japan with the new coronary therapeutic agent. The European scientists had an opportunity to discuss the problems and results personally with their Japanese colleagues. The Second Adalat Symposium was held in Amsterdam within a year with the purpose of bringing together mainly scientists within Europe. The results discussed in Tokyo have been extended and supplemented through additional experiences. Contributions in basic science are presented, but most important are those clinical studies, which support and extend proof of the drug's efficacy in humans. The editors wish to express their appreciation to all those responsible for contributing to this report and, in particular, to Dr. M. SPENGLER, Dr. F. EBNER and Dr. K. BRANDAU for their editorial help, and to Dr. W. BOTTGER for the preparation of the Subject Index. We hope that this publication will be a valuable contribution toward conveying information to physicians and scientists. DiisseldorfjWuppertal, Autumn 1975 W. LOCHNER' W BRAASCH' G. KRONEBERG Contents Introduction: W. LOCHNER Present Basis of Coronary Therapy: W. LOCHNER. With 11 Figures 2 Session I. Chemistry and Experimental Pharmacology (Chairmen: A. FLECKENSTEIN and K. LANDMARK) Pharmacology of Nifedipine: G. KRONEBERG. With 8 Figures 12 Discussion Remarks 19 The Chemistry of Nifedipine: F. BOSSERT. With 9 Figures 20 Pharmacokinetics of Adalat in Animal Experiments: K. PATZSCHKE, B.
Cuprins
Present Basis of Coronary Therapy.- Session I. Chemistry and Experimental Pharmacology.- Pharmacology of Nifedipine.- Discussion Remarks.- The Chemistry of Nifedipine.- Pharmacokinetics of Adalat in Animal Experiments.- Investigations on the Metabolism and Protein Binding of Nifedipine.- Discussion Remarks.- Experimental Pharmacological Investigations of Effects of Nifedipine on Atrioventricular Conduction in Comparison with Those of Other Coronary Vasodilators.- Discussion Remarks.- Studies on the Extracardial Effects of Nifedipine in Anesthetized Dogs.- Discussion Remarks.- Session II. Experimental Pharmacology.- Adalat, a Powerful Ca-Antagonistic Drug.- Ca-Dependent Changes in Coronary Smooth Muscle Tone and the Action of Ca-Antagonistic Compounds with Special Reference to Adalat.- Discussion Remarks.- Myocardial Oxygen Consumption under the Influence of Nifedipine (Adalat) in the Anesthetized Dog.- Discussion Remarks.- Hemodynamic Effects of Adalat in the Unanesthetized Dog.- Discussion Remarks.- Investigations on the Development of Collaterals, Coronary Flow, Tachyphylaxis and Steal Phenomenon in Dogs after Application of Adalat.- The Effect of Adalat on the Mechanical and Electrical Activity of Isolated Rat Cardiac Muscle, with Special Reference to Calcium Antagonism of the Compound.- Discussion Remarks.- Session III. Clinical Pharmacology.- Hemodynamic Studies on Adalat in Healthy Volunteers and in Patients.- Discussion Remarks.- Pharmacokinetics of Nifedipine-14C in Man.- Hemodynamic Studies on the New Coronary Therapeutic Drug Nifedipine (BAY a 1040).- Discussion Remarks.- Effect of Nifedipine (Adalat) on Myocardial Oxygen Extraction and Lactate Metabolism and ST-T Segment Changes in Patients with Coronary Insufficiency during Artificial Stimulation of the Heart.- Hemodynamic Effect of Nifedipine (Adalat) in Patients Catheterized for Coronary Artery Disease.- Discussion Remarks.- Session IV. Clinical Pharmacological Efficacy.- Comparison of the Effects of Adalat with Other Substances on the Myocardial Ischemia under Loading Conditions.- Discussion Remarks.- Left Ventricular Hemodynamics in Patients at Rest before and after Nifedipine (Adalat).- Discussion Remarks.- Adalat and Beta Blockers; the Mechanism Studied with Two Series of Work Tests in Two Groups of Patients with Angina Pectoris.- Adalat (Nifedipine) under Loading Conditions.- Discussion Remarks.- Results of a Comparative Study with Adalat: Phonomechano-Cardiograms in Normal Persons and Patients with Coronary Heart Disease.- Myocardial Circulation under Adalat in Different Phases of Coronary Diseases.- Discussion Remarks.- Session V. Clinical Aspects: Hemodynamics, Onset and Duration.- Coronary and Left Ventricular Dynamics under Nifedipine in Comparison to Nitrates, Beta-Blocking Agents and Dipyridamole.- Effect of Adalat (Nifedipine) on Left Ventricular Hemodynamics in Angina Pectoris (Comparative Study with Propranolol).- Discussion Remarks.- The Effect of Adalat on Coronary Circulation after Sublingual Administration.- Loading Tolerance after Adalat and Duration of Effect in Postmyocardial Infarction Studied in a Double-Blind Trial.- The Cardiopulmonary Loading Capacity in Healthy Persons and Patients with Coronary Heart Disease after Application of Adalat.- Remarks on Changes of ST Segment Depression during the Day.- Discussion Remarks.- Hemodynamic Study of Nifedipine Using Doppler Flowmetry.- Session VI. Clinical Aspects: Special Studies.- Clinical-Therapeutic and Hemodynamic Studies with Adalat, a New Coronary Active Substance.- Influence of Different Doses of Adalat on Angina Pectoris Induced by Exercise.- Discussion Remarks.- Nifedipine in the Treatment of Ischemic Heart Disease.- Clinical Observations on the Efficacy of Adalat Compared with a Pentaerythrityl Tetranitrate Preparation.- Discussion Remarks.- Clinical Studies on the Combined Effect of Various Antihypertensive Agents and Adalat.- Discussion Remarks.- Response of Intraocular Pressure in Normal Subjects and Glaucoma Patients to Single and Repeated Doses of the Coronary Drug Adalat.- Extracardial Effects of Nifedipine (Adalat): Measurements of Liver Blood Flow in Animals and Humans and of Peripheral Circulation in the Lower Limbs.- Discussion Remarks.- The Influence of Adalat on Pulmonary Pressure.- Comparison of the Effect of Adalat and Propranolol on Exercise Tolerance in Patients with Angina Pectoris.- Session VII. Clinical Aspects: Proof of Clinical Efficacy.- Nifedipine in Angina Pectoris: A Multicentric Clinical Trial.- Discussion Remarks.- An Interim Report on a Cooperative Double-Blind Clinical Trial with Nifedipine.- Discussion Remarks.- Results of a Double-Blind Study with Adalat under Short- and Long-Term Treatment.- Discussion Remarks.- Long-Term Therapy with Adalat. A Preliminary Report.- Discussion Remarks.- Survey and Summary of Results Obtained during the World-Wide Clinical Investigations of Adalat (Nifedipine).- Discussion Remarks.- Closing Remarks.